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co-delivery of pentaerythritol lipid A (PELA), an immunological adjuvant, and a model tumor antigen,
ovalbumin (OVA), separately loaded into polyanhydride particles (PA). In vitro experiments showed that
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specific CD8+ T lymphocyte population compared to PA-OVA alone. Furthermore, serum OVA-specific
antibody titers of mice vaccinated with PA-OVA/PA-PELA displayed a significantly stronger shift toward a
Th1-biased immune response compared to PA-OVA alone, as evidenced by the substantially higher
IgG2C:IgG1 ratios achieved by the former. Analysis of E.G7-OVA tumor growth curves showed that mice
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Abstract 
The primary objective of this study was to enhance the antitumor efficacy of a model cancer 
vaccine through co-delivery of pentaerythritol lipid A (PELA), an immunological adjuvant, and a model 
tumor antigen, ovalbumin (OVA), separately loaded into polyanhydride particles (PA). In vitro 
experiments showed that encapsulation of PELA into PA (PA-PELA) significantly enhanced its stimulatory 
capacity on dendritic cells as evidenced by increased levels of the cell surface costimulatory molecules, 
CD80/CD86. In vivo experiments showed that PA-PELA, in combination with OVA-loaded PA (PA-OVA), 
significantly expanded the OVA-specific CD8+ T lymphocyte population compared to PA-OVA alone. 
Furthermore, serum OVA-specific antibody titers of mice vaccinated with PA-OVA/PA-PELA displayed a 
significantly stronger shift toward a Th1-biased immune response compared to PA-OVA alone, as 
evidenced by the substantially higher IgG2C:IgG1 ratios achieved by the former. Analysis of E.G7-OVA 
tumor growth curves showed that mice vaccinated with PA-OVA/PA-PELA had the slowest average 
tumor growth rate. 
Keywords: Pentaerythritol Lipid A, Toll-like receptor-4 agonist, immunologic adjuvants, polyanhydrides, 
tumor-specific immune responses, cancer vaccines. 
Abbreviations: ANOVA: one-way analysis of variance; BMDCs: bone marrow-derived dendritic cells; 
CTLs: cytotoxic T lymphocytes; DCs: dendritic cells; DPBS: Dulbecco’s phosphate-buffered saline; ELISA: 
enzyme-linked immune-sorbent assay; FDA: food and drug administration; FITC: fluorescein 
isothiocyanate; IL: interleukin; LC-MS: liquid chromatography-mass spectrometry; MAPK: mitogen-
activated protein kinase; MPLA: monophosphoryl lipid A; MST: median survival time; NF-κB: nuclear 
factor kappa-light-chain-enhancer of activated B cells; OVA: ovalbumin; PA: polyanhydride; PBS: 
phosphate buffered saline; PE: phycoerythrin; PELA: pentaerythritol lipid A; SD: standard deviation; 
TLRs: Toll-like receptors. 
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BACKGROUND 
Cancer vaccines represent a promising approach to combating tumors and, in particular, their 
metastases without causing the deleterious side effects often associated with conventional 
chemotherapy1, 2. The primary goal of cancer vaccines is to harness the host’s own immune system to 
provide specific antitumor immunity capable of mediating tumor destruction and protecting against 
metastasis and tumor recurrence3-6. With steady growth in research toward finding effective approaches 
to treating cancer, immune-based therapies have undergone a considerable resurgence in the past 
decade1, 7, 8. Among all immunotherapies, cancer vaccines are the most common type currently being 
explored9. An essential component of a cancer vaccine is the tumor antigen(s) which can be delivered in 
a purified, tumor cell-derived (e.g., cell lysate) or encoded form10, 11. However, many tumor-associated 
antigens are poorly immunogenic, due primarily to tolerance mechanisms, and require an adjuvant 
and/or innate immune stimulus to promote their immunogenicity1, 12. In addition, the tumor 
microenvironment is known to be immunosuppressive13, 14. Thus, in order to enhance the potency of 
cancer vaccines, adjuvants capable of stimulating dendritic cell (DC) maturation, by binding to Toll-like 
receptors (TLRs), are often included in the formulation. These adjuvants can enhance tumor-specific 
adaptive immune responses12, 15-18. 
From a research standpoint, available licensed adjuvants that can substantially enhance 
antitumor cytotoxic T cell activation are limited19, 20. Developing a vaccine formulation containing a TLR4 
ligand has been a subject of wide research interest over the last few decades21. This has culminated in 
the generation of a number of prospective therapeutic cancer vaccines or prophylactic vaccines against 
cancer-causing viruses that have reached clinical trials or become FDA-approved, respectively22, 23. These 
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vaccines contain monophosphoryl Lipid A (MPLA; a TLR4 agonist24) which is derived from Salmonella 
Minnesota. Recently, Oncothyreon Inc. (now known as Cascadian Therapeutics Inc.) has expanded the 
immunological adjuvant repertoire by synthesizing a more potent and safer version of lipid A (as 
compared to MPLA) known as pentaerythritol lipid A, or PET lipid A (PELA)25. PELA (C95H181N2O19P), a lipid 
A analog, is a hexa-acylated monosaccharide monophosphorylated ligand which is fully synthetic and 
thus is less subject to batch-to-batch variation and has greater quality control than MPLA26. PELA 
displays strong immunostimulatory (i.e., adjuvant) properties and can boost adaptive immunity by 
binding to TLR4 expressed on the surface of DCs26, 27. The acyl chains in PELA (Supplementary Material; 
Figure S1) are essential for binding to TLR4, which has been reported to trigger NF-κB and MAPK 
signaling pathways, involved in regulating and directing cellular immune responses28, 29. Due to the 
promising results that PELA has shown in preclinical studies, it has been advanced into clinical trials and 
incorporated into a liposomal formulation, ONT-10, which is a therapeutic cancer vaccine designed to 
treat cancers that express mucin-1, such as breast cancer30, 31.  
Particulate delivery systems for cancer vaccine applications have been shown, in preclinical 
settings, to be an advantageous approach to delivering antigen and adjuvant compared to delivery in 
soluble form32-36. Not only does loading these components into particles results in protection from 
premature degradation, but particles also ensure more efficient delivery to DCs and sustained local 
availability for uptake by DCs32. In particular, polyanhydrides (PAs) have shown promise as 
biocompatible and biodegradable polymers37, 38 and have been used in some marketed controlled-
release medical products such as Gliadel® (PA-based wafer containing carmustine for treating 
glioblastoma multiforme) and Septacin™ (PA-based beads loaded with gentamycin for treating 
osteomyelitis)39-41. PA and PELA have the potential to act at least additively in enhancing antigen-specific 
immune responses since both can bind to and activate TLR426, 27, 42. Since PA particles also offer the 
aforementioned advantages in addition to their adjuvanticity43-46, there is the possibility for synergistic 
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enhancement of immune responses when used together as vaccines. In this study, the primary goal was 
to enhance the immune response and the antitumor efficacy of a previously reported PA-based model 
cancer vaccine, comprising of PA particles encapsulating ovalbumin (PA-OVA)47, by adding PA-PELA to 
the formulation. The encapsulation of PELA was found to enhance the stimulation of DCs and increase 
levels of antigen-specific CD8+ T cells. These enhancements in immunogenicity due to the combination 
of PA-OVA and PA-PELA were also reflected in a trend toward increased antitumor activity and 
decreased tumor progression in a prophylactic mouse tumor model, when compared to PA-OVA alone, 
suggesting the potential of PA-PELA adjuvants for use in cancer vaccines. 
METHODS 
Particle fabrication and characterization 
PELA and OVA encapsulating PA particles were prepared using single and double emulsion 
solvent-evaporation techniques, respectively. Details of the fabrication and characterization of particles 
are provided in the Supplementary Material. 
In vitro release kinetics 
Release of OVA from PA particles: Samples of PA particles encapsulating OVA (≈ 30 mg) were dispersed 
into 5 mL of phosphate buffered saline (PBS) (Sigma-Aldrich, St. Louis, MO) and incubated in the orbital 
incubator shaker (New Brunswick Scientific Co. Inc., Edison, NJ) set at 37 °C and 300 rpm for one month. 
The amount of OVA released from particles into the PBS was measured at predetermined time intervals 
(1, 2, 4, 7, 10, 14, 20, and 30 days) and aliquots (0.5 mL) of the release medium were withdrawn and 
replaced by the same volume of fresh PBS at each time interval. Supernatants were stored at –20 °C 
until OVA content was measured by the bicinchoninic acid protein assay (as described in the 
Supplementary Material). The experiment was performed in triplicate, and the results were expressed 
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as the mean of cumulative OVA-release into PBS determined as a function of time ± standard deviation 
(SD). 
Release of PELA from PA particles: The release kinetics of PELA, which is poorly water-soluble as a result 
of its long hydrophobic acyl chains, was studied using PBS solution containing 1% v/v Tween-80 (Fisher 
Scientific, Fair Lawn, NJ). Tween-80, a nonionic surfactant, was added to the release medium to enhance 
PELA solubility and fulfill the sink conditions. Samples of PA particles (≈ 10 mg) were dispersed in 10 mL 
of PBS/Tween-80 solution and incubated in the orbital incubator shaker set at 37 °C and 300 rpm for a 
period of one month. The amount of PELA released from particles was measured at predetermined time 
intervals (same as OVA-release time points), and aliquots (1 mL) of the release medium were withdrawn 
and replaced by the same volume of fresh PBS/Tween-80 solution at each time interval to maintain a 
constant volume of release medium. Samples were stored frozen at –20 °C until PELA content was 
quantified by liquid chromatography-mass spectrometry (LC-MS) (as described in the Supplementary 
Material). The results were expressed as the mean of cumulative PELA release into PBS/Tween-80 
determined as a function of time in three parallel experiments ± SD. 
In vitro DC stimulation 
In this study, the stimulatory effect of PELA encapsulated into particles and in its soluble form 
was assessed using DCs, which are professional antigen-presenting cells capable of efficiently priming 
naïve T cells48, 49. DCs were obtained from a C57BL/6J mouse through isolation of the bone marrow. 
Briefly, tibia and femur were extracted, and surrounding muscles were removed. This was followed by 
trimming both ends of the bone and flushing the media through the bone to collect the marrow. Primary 
cells were harvested and grown on Bacteriological Petri dishes in Roswell Park Memorial Institute 
medium (RPMI 1640) supplemented with 10 mM HEPES buffer, 1 mM sodium pyruvate, 0.1 mM minimal 
essential medium nonessential amino acids MEM-NEAA, 2 mM GlutaMAX (Life Technologies, Grand 
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Island, NY), 50 mM 2-mercaptoethanol (Sigma-Aldrich), 50 ng/mL gentamicin sulfate (IBI Scientific, 
Peosta, IA), 10% fetal bovine serum (Atlanta Biologicals, Flowery Branch, GA), and 20 ng/mL of murine 
granulocyte-macrophage colony stimulating factor (PeproTech, Rocky Hill, NJ), and incubated in a well-
controlled environment at 37 °C with 5% CO2. Bone marrow-derived dendritic cells (BMDCs) were 
harvested at day 10 of culture, seeded in 12-well Cellstar plates (Greiner Bio-One, Germany) at a density 
of 3 x 105 cells/well, and incubated for 6 h. The cells were next stimulated by adding the treatments (1 
and 3 µg PELA either encapsulated or soluble) and incubating for 24 h. After incubation with designated 
treatment, cells were flushed with existing media, collected and centrifuged for 5 min at 4 °C using 
Eppendorf Centrifuge 5804-R (Eppendorf, Westbury, NY) set at 230 xg. Also, cell culture supernatants 
were collected to measure interleukin (IL-10 and IL12p70) concentrations using cytokine-specific mouse 
enzyme-linked immune-sorbent assay (ELISA) kits (Thermo Fisher Scientific, San Diego, CA), as per the 
manufacturer’s instructions. Cells collected by centrifugation were stained with an anti-CD11c-
fluorescein isothiocyanate (FITC) and either anti-CD80-phycoerythrin (PE) or anti-CD86-PE (eBioscience, 
San Diego, CA) using a standard direct immunofluorescence procedure. Controls involved staining DCs 
with FITC- or PE-conjugated isotype antibodies. Samples were run through a BD FACScan flow cytometer 
(Becton Dickinson, Franklin Lakes, NJ) in triplicate, and data were analyzed with FlowJo software (Tree 
Star, Ashland, OR). Results were expressed as a percentage of CD80+/CD86+ DCs. 
Animal studies 
Mouse strains: A murine tumor model was used for the evaluation of prophylactic cancer vaccine 
formulations. Wild-type C57BL/6J mice were purchased from Jackson Laboratory (Bar Harbor, ME). 
Animals were maintained and preserved at the Medical Laboratories at the University of Iowa and kept 
on a daily 12 h light/12 h dark cycle. All animal experiments were performed in accordance with the 
University of Iowa guidelines for the care and use of laboratory animals. In all experiments, 6–8 week-
old female mice were used. Mice were anesthetized via intraperitoneal injection of the ketamine-
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xylazine mixture (dose: 87.5 mg/kg ketamine and 12.5 mg/kg xylazine) per mouse prior to vaccine 
administration or performing any other in vivo experiments. 
Vaccination and in vivo experiments schedule: To test the in vivo efficacy of prepared formulations, 
mice were randomly divided into three groups and treated with subcutaneous (rear dorsal flank) 
injections of the following treatment groups: (I) naïve (i.e., unvaccinated), (II) PA-OVA, and (III) PA-
OVA/PA-PELA. Prepared PA particles were dispersed in 1X Dulbecco’s phosphate-buffered saline (DPBS, 
pH 7.4) (Life Technologies) immediately prior to vaccination. Doses of 50 μg OVA and 20 μg PELA per 
mouse were regularly used during prime vaccination on the day (0) and booster vaccination a week 
later. These doses were based on a previous study using poly(D,L-lactide-co-glycolide) particles loaded 
with OVA and PELA where significant effects on OVA-specific CD8+ T cell responses were observed in 
vivo when doses of 60 and 18 µg were used, respectively50. It is well-established that encapsulation of 
antigen and/or adjuvant into particles enhances vaccine potency compared to delivery in soluble form35, 
50, 51. Specifically, control groups such as soluble OVA alone and soluble OVA + soluble PELA have already 
been tested and have been shown to be poorly immunogenic compared to their particulate 
counterparts50. In addition, we have previously tested the in vivo efficacy of PA-OVA against soluble OVA 
and blank PA particles (i.e., containing no OVA), and the results indicated that 75% of mice survived in 
the PA–OVA group (at day 28 post-tumor challenge) while 0% of mice survived in the groups treated 
with either blank particles or soluble OVA52. Therefore, such controls were not included in this current 
animal study to align with ethical standards regarding minimizing the numbers of animals used in 
research experiments. On day 14 post-prime vaccination, tumor-specific CD8+ T lymphocyte levels (also 
known as cytotoxic T lymphocytes, CTLs) were measured in the peripheral blood harvested through 
submandibular bleeds. On day 28 post-prime vaccination, tumor-specific IgG1 and IgG2C antibody titers 
were measured in the serum harvested through submandibular bleeds. A week later, mice were 
challenged with tumor cells. 
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Cell-mediated immunity: T cell receptors (TCR), expressed on CTLs, specifically recognize and bind to 
major histocompatibility complex (MHC) class I. MHC tetramer assay and direct immunofluorescence 
technique enable the direct detection and quantification of tumor-specific CTLs within blood samples. 
Using submandibular bleeding technique, approximately 200 μL of mouse peripheral blood was 
collected into tubes containing 3 mL of ACK (ammonium-chloride-potassium) lysing buffer, and the 
samples were incubated at room temperature for 5 min. After incubation, peripheral blood lymphocytes 
(PBLs) were washed twice with a complete medium using Eppendorf Centrifuge 5804-R set at 230 xg, 4 
°C, for 5 min. Then, PBLs were resuspended in 150 μL of ice-cold FACS (fluorescence-activated cell 
sorting) buffer and transferred to a v-bottom 96-well plate (Corning, Kennebunk, ME) incubated on ice. 
This was followed by centrifugation (at the same previous conditions), supernatants were discarded, and 
PBLs were resuspended in 50 μL of anti-mouse CD16/CD32 Fc receptor block (clone 93) (eBioscience) in 
FACS buffer and incubated for 15 min. Subsequently, 50 μL of H-2Kb SIINFEKL class I iTAg™ MHC 
tetramer (Kb-OVA257) labeled with PE (MBLI, Woburn, MA) in FACS buffer was added in the dark, and 
samples were incubated for 30 min. After incubation, 100 μL of a mixture of fluorescein isothiocyanate 
(FITC)-labeled rat anti-mouse CD8 and PE-Cy5-labeled hamster anti-mouse CD3 (eBioscience) antibodies 
in FACS buffer was added in the dark and incubated for 20 min. After incubation, PBLs were washed 
twice with FACS buffer to remove the unbounded antibodies. Subsequently, 100 μL of 1X Perm/wash 
buffer (BD Biosciences, San Jose, CA) was added, and this was immediately followed by centrifugation 
for 15 min at 660 xg and 4 °C. Finally, PBLs were resuspended in FACS buffer, samples were acquired 
using BD FACScan flow cytometer, and data were analyzed with FlowJo software. Results were 
expressed as a percentage of total CD3+ CD8+ T lymphocytes in peripheral blood that were positive to 
tetramer staining assay. 
Antibody-mediated immunity: The titers of tumor-specific IgG antibodies, IgG1 and IgG2C, were 
measured using ELISA, as described previously47. In brief, mice were bled from the submandibular area, 
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and to harvest sera, blood samples were incubated at room temperature for one hour. After incubation, 
blood clots were removed using clean tweezers, and the samples were centrifuged for 10 min using an 
Eppendorf Centrifuge 5804-R set at 3,000 xg and 4 °C. Supernatants (sera) were collected and stored at 
–80 °C until use. In the meanwhile, Immulon® 2HB flat-bottom microtiter 96-well plates (Thermo Fisher 
Scientific, Rochester, NY) were coated with 100 μL of PBS containing 0.5 μg OVA. Using OVA-coated 
plates and PBS containing 0.05% v/v Tween-20 (Sigma-Aldrich), sera samples were serially diluted and 
incubated overnight at room temperature. This was followed by incubation for 3 h at room temperature 
with either goat anti-mouse IgG1 (or goat anti-mouse IgG2C) antibody conjugated with alkaline 
phosphatase (Southern Biotech, Birmingham, AL). Subsequently, 100 μL of p-nitrophenyl phosphate 
(pNPP) in TRIS buffer (Sigma-Aldrich) was added in the dark. After 30 min, the absorbance was 
measured at 405 nm using a SpectraMax® Plus 384 microplate reader (Molecular Devices LLC, 
Sunnyvale, CA). To remove any proteins or antibodies that were not specifically bound, plates were 
washed three times with 150 μL of PBS/Tween-20 solution between all reagent addition steps. The 
reciprocal of mouse sera dilution (highest dilution at which the absorbance is three-times greater than 
those of negative control) was reported as serum antibody titers. 
Tumor challenge: Five weeks post-prime vaccination, all mice were subcutaneously challenged with 2 x 
106 E.G7 cells (expressing OVA), purchased from American Type Culture Collection (ATCC®, Manassas, 
VA), suspended in 100 μL of sterile 1X DPBS. Cells were injected contralaterally to the vaccination site. 
Tumor progression was monitored regularly over time for the subsequent two months (using digital 
caliper), and tumor volumes were calculated as described in Equation 1. To minimize pain and 
discomfort, mice were euthanized when the tumor size exceeded 20 mm at the largest diameter or 10 
mm in height. 
Equation 1: Tumor Volume = diameter1 x diameter2 x height x (π/6) 
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Statistical analysis 
Data were initially analyzed by one-way analysis of variance (ANOVA) using F-test which was 
followed by a Tukey’s multiple comparison test to compare all pairs of treatments. To characterize the 
tumor progression and assess differences in the pattern of change over time in the mean tumor volumes 
between the two vaccinated groups (i.e., PA-OVA alone and PA-OVA/PA-PELA), longitudinal data of the 
tumor growth profiles of mice in both vaccinated groups were analyzed with a linear mixed-effects 
model using SAS PROC MIXED (SAS Institute Inc., Cary, NC). Initial analysis of survival data was 
performed by log-rank (Mantel-Cox) test using GraphPad-Prism 7 (GraphPad Software, La Jolla, CA). 
Using SAS 9.4, further statistical analysis was performed by pairwise comparisons and data were 
analyzed using the log-rank test (Tukey-Kramer adjusted). In all tests, differences were considered 
statistically significant when p<0.05. 
RESULTS 
Properties of PA particles 
PA-OVA particles, prepared by the double emulsion method, had an average diameter of almost 
1 µm while PA-PELA particles fabricated by the single emulsion method had an average diameter of 
nearly 0.5 µm (Table 1). All particles exhibited a narrow size distribution with average PDI values being < 
0.2 (Table 1). In addition, all formulations possessed negatively charged surfaces (Table 1). PELA-PA 
particles were quantified using a validated LC-MS method (Supplementary Material; Figure S2), and it 
was found that the encapsulation efficiency of PELA was comparable to that of OVA (Table 1). Analysis 
of scanning electron microscope photomicrographs demonstrated that the particles were spherical in 
shape with smooth surfaces (Figure 1). 
In vitro release kinetics of PA-OVA and PA-PELA particles 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
12 
 
Upon dispersal of PA particles into release media, both OVA- and PELA-loaded PA particles 
demonstrated rapid short burst releases (Figure 2). A burst release was followed by a slower sustained 
release of the payloads over time. By day 30, OVA and PELA cumulative release from PA particles had 
reached 89% and 88%, respectively. Thus, it was found that the release of PELA exhibited a similar trend 
to the OVA cumulative release. Release profiles were also fit to a zero-order release kinetic model with 
burst effect, and the analysis revealed that the model adequately captured the data, and PA particles 
exhibited a steady increase in the release of cargo that approximated to zero-order release kinetics 
(Supplementary Material; Figure S3). 
Evaluation of the effect of PA-PELA on the expression of CD80, CD86, IL-10, and IL-12 by BMDCs 
BMDCs were harvested at day 10 of culture, at which point nearly 90% of the cells were CD11c 
positive as analyzed by the BD FACScan flow cytometer (data not shown). Prior to experimental assays, 
cell viability was tested by Trypan blue exclusion, and results indicated that the cell viability was greater 
than 95%. Results of surface staining of BMDCs revealed that PELA-PA particles promoted the 
upregulation of both CD80 and CD86, and this was significantly greater than untreated BMDCs, soluble 
PELA, PA particles alone, or a physical mixture of PA particles with PELA (PA + PELA), used at the 
equivalent doses (Figure 3.1). This clearly demonstrates that delivery of PELA in particulate form 
enhanced its costimulatory effect. In addition, the results showed that PA particles alone promoted the 
upregulation of both CD80 and CD86, which further demonstrates that PAs possess self-adjuvanting 
properties. Also, it was observed that the costimulatory effect of PAs was dose-dependent. The results 
also suggest that PELA and PAs worked synergistically and promoted stimulation of BMDCs, and the 
combination of these two is superior to PA or PELA alone. In addition, it was shown that while empty PA 
particles had little or no effect on both IL-12p70 and IL-10 secretion, PA-PELA had a significant impact on 
increasing the expression of both cytokines (compared to the same dose of soluble PELA). Interestingly, 
as the dose increased from 1 to 3 µg PELA (encapsulated in PA particles; PA-PELA), the relative levels of 
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secretion of IL-10:IL-12p70 decreased significantly (t-test; p<0.0001) (Figure 3.2), suggesting that high 
doses of PA-PELA may preferentially favor the induction of Th1-type responses. 
Assessment of Immunogenicity 
Groups of immunocompetent mice were vaccinated (prime/boost on days 0/7) with a 
heterogeneous mix of PA particles separately loaded with OVA or PELA (PA-OVA/PA-PELA), or with a 
homogenous suspension of particles loaded with OVA alone (PA-OVA), and both humoral and cellular 
OVA-specific immune responses were assessed. Tetramer staining data showed that mice vaccinated 
with PA-OVA particles alone did not induce a significant increase in OVA-specific CD8+ T cell levels in the 
peripheral blood, however, when combined with PA-PELA particles, OVA-specific CD8+ T cell levels 
increased significantly compared to unvaccinated mice (Figure 4.1). In terms of humoral OVA-specific 
immune responses, co-delivery of PA-PELA with PA-OVA particles did not significantly enhance OVA-
specific IgG1 antibody titers compared to when PA-OVA particles were administered alone (Figure 4.2A). 
However, co-delivery of PA-PELA with PA-OVA particles significantly improved the production of OVA-
specific IgG2C compared to mice vaccinated with PA-OVA alone (Figure 4.2B). Also, the IgG2C:IgG1 ratio 
for mice immunized with PA-OVA/PA-PELA formulation was significantly higher compared to mice 
vaccinated with PA-OVA alone, indicating a correspondingly higher Th1-biased immune response (Figure 
4.2C). 
Evaluation of tumor progression and survival 
Five weeks post-prime vaccination, groups of mice were challenged with a lethal dose of E.G7 
cells, and tumor growth and survival were subsequently recorded. As expected, naïve mice had tumors 
that grew rapidly compared to vaccinated mice, and four mice from the control group were euthanized 
on day 16 post-tumor challenge as their tumors already reached a predetermined size limit (Figure 5.1). 
In contrast, mice vaccinated with either PA-OVA alone or PA-OVA/PA-PELA had tumor volumes that 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
14 
 
were, on average, significantly smaller than those of unvaccinated mice (as tested on day 16 using 
ANOVA, p<0.001). In addition, it was observed that 60% of mice treated with PA-OVA/PA-PELA were 
tumor free on day 16 post tumor challenge whereas all mice in the other two groups had detectable 
tumors. Also, longitudinal data of the tumor growth of mice in both vaccinated groups (i.e., PA-OVA 
alone and PA-OVA/PA-PELA) were analyzed using a linear mixed-effects model. The analysis revealed 
that the combination of PA-OVA and PA-PELA caused a significant reduction in the tumor progression 
compared to mice administered with PA-OVA alone (p<0.001). Co-delivery of PA-PELA and PA-OVA 
particle formulations also marginally extended the median survival time (MST = 35 days) when 
compared to the delivery of PA-OVA particles alone (MST = 31.5 days), albeit not significantly (Figure 
5.2). Survival analysis also revealed that both vaccine strategies resulted in a statistically significant 
extended survival compared to the naïve control group (MST = 18 days) (p<0.001). 
DISCUSSION 
We have previously demonstrated that PA particles loaded with OVA were capable of protecting 
against challenges with OVA-expressing tumor cells when the particles were used as prophylactic 
vaccines in immunocompetent mice47. Here, we attempted to further improve the immunogenicity of 
OVA-loaded PA particles through co-delivery of the encapsulated TLR-4 agonist, PA-PELA. It has been 
previously shown by others and us that providing TLR agonists in a particulate form, using different 
polymers, generates more potent vaccines as opposed to when soluble TLR agonists are used35, 50, 53. 
Thus, side-by-side comparisons of two formulations were carried out. One treatment formulation 
involved PA-OVA alone, a homologous suspension of OVA-loaded PA particles. The second treatment 
formulation involved a heterologous blend of PA-OVA and PA-PELA. In the particle preparation process, 
PELA and OVA were independently encapsulated in order to maximize the loading for each component 
and to ensure that the dosage ratio of OVA:PELA delivered in vivo was similar to a previous study 
involving a different polymer50. While some studies have shown that co-loading can be advantageous in 
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terms of stimulating strong immune responses, we and others have found that simultaneous delivery of 
the antigen and adjuvant using independently loaded particles results in similar enhancement of 
immune responses17, 50, 54, 55. This is because separately encapsulated antigen and adjuvant will not 
necessarily remain segregated in vivo as both types of particle formulations could be internalized by the 
same DCs, which generally have the capacity to internalize more than one particle at a time56. 
Specifically, our group has previously demonstrated that co-loading PELA and OVA into the same 
poly(lactide-co-glycolide)-based particles generated similar cellular immune responses and provided 
similar tumor protection to independently loaded particles50. Analysis of in vitro release profiles for both 
PA-OVA and PA-PELA demonstrated an initial burst release followed by sustained delivery of both 
antigen and adjuvant over time (up to 30 days), implying that the payloads were homogeneously 
distributed throughout the particles. Interestingly, the release kinetics of each of the payloads were 
similar despite their distinct chemical properties (e.g., PELA is a much more hydrophobic molecule than 
OVA). Thus, it appears that the release kinetics of these payloads were mainly determined by polymer 
degradation rate although the presence of proteins and enzymes in vivo may also have the potential to 
modulate the release profile. This observation can be explained by the fact that PA particles 
predominately degrade through surface erosion which make them appropriate biomaterials for 
sustained release of payloads57-59. The sustained release witnessed may be advantageous in terms of in 
vivo vaccine applications for at least two reasons. The first is that, in the 1-2 days subsequent to 
vaccination, the payload still present inside the particles is likely to be substantial and therefore capable 
of exerting significant downstream consequences, upon uptake by DCs, in terms of DC activation and 
immune response stimulation. The second reason is that those particles potentially not taken up by DCs 
in the initial 1-2 days may act as a depot for both PELA and OVA for a period of days to weeks, which 
may be beneficial in terms of generating OVA-specific adaptive immune responses. Recently, we 
reported on the uptake of PA particles, and the results demonstrated that PA particles are readily and 
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efficiently internalized by BMDCs56. Also, it is of note that particle size plays a crucial role in determining 
their ultimate fate and the magnitude of the immune response32, 60. Generally, larger particles (> 100–
200 nm) remain at the vaccine injection site and require uptake by migratory DCs in order to be 
delivered to the local draining lymph node while smaller particles (< 100–200 nm) can potentially travel 
independently to the draining lymph node where they can be taken up by the resident dendritic cells61, 
62. Since the size of both particle formulations (PA-OVA and PA-PELA) is above that threshold, it would 
be expected that particles would remain in situ until being internalized by peripheral DCs. 
In vitro studies on DC activation by PA-PELA were performed to test if this formulation had the 
capacity to further enhance, over soluble PELA, the costimulatory potential of DCs by inducing their 
maturation as defined by the up-regulation of CD80 and CD8663. Generally, naïve T cells require 
costimulatory signals (in addition to the engagement of the T cell receptor) in order to become activated 
into an effector phenotype capable of proliferation and imparting function in an antigen-specific 
manner. Two well-studied costimulatory surface proteins are CD80 and CD8663. Our in vitro studies 
indicated that the expression of CD80 and CD86 were significantly upregulated on the surface of DCs 
when the cells were cultured with PA-PELA compared to when DCs were cultured with soluble PELA 
alone or soluble PELA plus empty PA particles. This further supports the observation that the 
encapsulation of PELA into particles provides additional advantages compared to soluble counterparts. 
Interestingly, incubation of DCs with PA-PELA resulted in a synergistic increase in expression levels of the 
costimulatory proteins compared to when both components were added independently to the same 
culture, where an additive increase in expression was observed (Figure 3.1). Finally, it was found that 
empty PA particles per se induced up-regulation of CD80 and CD86 on DCs, further supporting the body 
of literature on the adjuvanticity of PA particles43-46. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
17 
 
The above in vitro demonstration of potent DC activation by PA-PELA spurred further studies in 
vivo to assess the immunostimulatory potential of these particles when used in combination with PA-
OVA as a cancer vaccine. It was shown that the combination of PA-PELA and PA-OVA induced a modest 
yet significant increase in OVA-specific CD8+ T cell levels in the peripheral blood of vaccinated mice 
within two weeks of the priming vaccination (Figure 4.1). Significant increases were also seen in the 
titers of OVA-specific IgG2C antibodies (four weeks after prime), indicating a push, albeit marginal, 
toward a Th1-type immune response. This was in contrast to when PA-OVA was used alone as a vaccine 
and demonstrated no significant increase in either of the aforementioned parameters when compared 
to mice receiving no vaccination. When tested for the capacity of the combination of PA-PELA and PA-
OVA to protect against a subsequent tumor challenge, a significant increase in antitumor activity (as 
assessed through average tumor volume measurements) was observed compared to mice vaccinated 
with PA-OVA alone (Figure 5.1). The reasons for the lack of a significant increase in the survival study are 
at this stage unknown but may stem from insufficient DC stimulation subsequently resulting in 
insufficient CD8+ T cell activation. As mentioned above, the observed increases in OVA-specific T cells in 
the peripheral blood of mice immunized with PA-PELA and PA-OVA, while being significant when 
compared to mice vaccinated with PA-OVA alone, were marginal and perhaps the protective response 
may not have benefited from higher levels of OVA-specific CD8+ T cells being generated. It is possible 
that insufficient stimulation of Th1-leaning cytokine production, such as IL-12, or alternatively an 
inappropriate ratio of Th1:Th2 cytokines hindered the expansion and/or function of the OVA-specific 
CD8+ T cells. Our ELISA studies, where both IL-12p70 and IL-10 production by DCs co-cultured in vitro 
with PA-PELA were measured, revealed that the ratio of production levels of these cytokines was dose-
dependent where 1 μg of PELA (encapsulated in PA particles; PA-PELA) cultured with DCs resulted in an 
approximate 1.3:1 ratio of IL-10:IL-12 while 3 μg of PELA (PA-PELA) resulted in a 0.5:1 ratio (Figure 3.2). 
Therefore, at higher doses of PA-PELA, a greater skewing toward a Th1-type response was observed. IL-
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12 has been shown to enhance CD8+ T cell responses while IL-10 has often been associated with 
abrogation of Th1 responses64. We, therefore, expect that increased amounts of PA-PELA or both PA-
PELA and PA-OVA would increase the magnitude of the antigen-specific immune response stimulated 
even further. 
Immunosuppressive strategies recruited by tumors and inadequate specificity of existing cancer 
treatments are among the major limitations to the current therapies, and the vast majority of approved 
immunotherapies utilize systemic delivery of cells or immunomodulators which makes addressing these 
hurdles more challenging65. Biomaterials such as PAs offer a unique platform to address these 
challenges by harnessing the advantages of therapeutic targeting, co-delivery, sustained release, 
activation/maturation of DCs, and promotion of CTLs. Enhancing the immune responses against tumors 
through particle-based delivery of TLR(s) can further improve the clinical impact of biomaterials in 
cancer immunotherapy. In previously published studies, we reported that the TLR-9 agonist CpG ODN 
was prone to hinder rather than improve the immunogenicity and antitumor activity of PA particle-
based vaccines47. In contrast, in this study, it was demonstrated that the TLR4 agonist (PELA) when 
encapsulated in PA particles, significantly improved OVA-specific CD8+ T cell responses, a result 
potentially attributable to the effect observed in vitro where DCs were induced to express significantly 
higher amounts of CD80/CD86 and IL-12p70. This improvement in the immunogenicity may explain the 
trend toward slower tumor progression and extended survival. Further studies on the role of increased 
doses of PA-PELA in vivo on the antitumor potential of the formulation need to be performed. Also, the 
vaccine formulation will need to be tested in a therapeutic setting and using a more clinically relevant 
tumor model, and in the presence and absence of immune checkpoint inhibitors. 
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FIGURE LEGENDS 
Fig. 1: Electron photomicrographs of polyanhydride particles. (A) PA-OVA (scale bar is 1 μm); (B) PA-
PELA (scale bar is 0.5 µm); (C) PA empty particles (scale bar is 0.5 μm). 
Fig. 2: Cumulative percentage release of OVA (●) and PELA (○) from polyanhydride particles over time.  
Data are plotted as mean ± SD. 
Fig. 3.1: Stimulatory effect of PELA on BMDCs (in vitro) via direct fluorescence staining. BMDCs were 
stained with anti-CD80 and CD86. Representative histogram plots display relative surface expression 
intensity for CD80 and CD86 at 1 μg PELA. Data are plotted as percentage of CD80+/CD86+ DCs ± SD, n = 
3. *p< 0.05, ***p<0.001. 
Fig. 3.2: In vitro IL-10 and IL-12p70 production by BMDCs exposed to PA with or without PELA. Levels 
of IL-10 and IL-12p70 were assessed in the supernatants by ELISA 24 h post incubation of BMDCs with 
the designated treatment. Results are plotted as mean ± SD, n = 3. *p< 0.05, ***p<0.001. 
Fig. 4.1: Cell-mediated OVA-specific immune responses in mice vaccinated with different 
polyanhydride particle-based formulations containing OVA ± PELA. Data are plotted as mean ± SEM, n 
= 10. **p<0.01, ***p<0.001. 
Fig. 4.2: Humoral OVA-specific antibody responses in mice vaccinated with different polyanhydride 
particle-based formulations containing OVA ± PELA. (A) Serum titers of OVA-specific IgG1; (B) Serum 
titers of OVA-specific IgG2C; (C) IgG2C:IgG1 ratio. Data are plotted as mean ± SEM, n = 10. ***p<0.001. 
Fig. 5.1: Prophylactic antitumor effect of vaccinating mice with different polyanhydride particle-based 
formulations containing OVA ± PELA. Each curve represents the tumor growth for each individual 
mouse except in the average tumor growth graph where the average tumor volume (mean ± SEM) is 
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reported; naïve (); PA-OVA (); PA-OVA/PA-PELA ( ). Numbers in parentheses represent the 
percent of mice with complete tumor regressions. In the average tumor growth graph, # indicates the 
statistical difference between vaccinated groups and naïve control group at day 16 post-tumor challenge 
(ANOVA, p<0.001) while  refers to the statistical difference between the two vaccinated groups 
(longitudinal data analysis with the linear mixed-effects model, p<0.001). 
Fig. 5.2: Survival curve of mice bearing E.G7-OVA tumors. Prior to tumor challenge, mice were 
vaccinated with the indicated formulation; naïve (); PA-OVA (); PA-OVA/PA-PELA ( ). The dotted 
line represents the median (50%) survival while # indicates the statistical difference between vaccinated 
groups and naïve control group (p<0.001). 
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Table 1: Properties of polyanhydride particles encapsulating OVA or PELA. 
 PA-OVA 
particles 
PA-PELA 
particles 
Empty PA 
particles 
Particle Size (nm) 981 ± 18 486 ± 6 497 ± 5 
Polydispersity Index (PDI) 0.15 ± 0.03 0.11 ± 0.04 0.11 ± 0.04 
Zeta Potential (mV) –31.2 ± 4.5 –19.8 ± 0.1 –17.0 ± 0.2 
Loading Capacity (μg per mg of particles) 7.7 ± 0.2 4.3 ± 0.2 - 
Encapsulation Efficiency (%) 35.8 ± 1.1 35.6 ± 1.7 - 
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Graphical Abstract 
The study indicated that the immunostimulatory effect of PELA on DCs was significantly improved upon 
encapsulation into PA particles. The study also demonstrated that incorporation of PELA significantly 
enhanced the immunogenicity of PA particle-based cancer vaccines as indicated by significantly 
increased levels of OVA-specific CD8+ T cells and skewed the immune response toward a Th1 phenotype. 
Furthermore, the PELA containing formulation, when used in combination with PA-OVA, demonstrated a 
significant decrease in the rate of tumor progression when compared to PA-OVA alone. Taken together, 
these results emphasize the potential for PA-PELA to be utilized as an immunological adjuvant in cancer 
vaccines. 
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